Find Funding Opportunities

The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-19-171 "Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)".

This notice informs applicants of an extension to PA-18-937 "Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 5, 2022. This FOA will expire May 8, 2022.

This notice informs applications of an extension to PA-18-939 "Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 16, 2022. This FOA will expire May 8, 2022.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-20-316 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.

The National Institute of Neurological Disorders and Stroke (NINDS) will be hosting an informational webinar on August 17, 2021 from 1PM 2PM (Eastern Time) for all potential applicants interested in these companion Funding Opportunity Announcements (FOAs): RFA-NS-21-009: Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed) RFA-NS-21-033: Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed) These two FOAs together aim to facilitate teaching of fundamental principles of rigorous biomedical research by developing a new online educational resource for use by a broad range of researchers in an array of learning environments. CENTER will support the establishment of a center to build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research. METER will support the compilation and refinement of the core scholarly content of educational units within this online resource.

The purpose of this notice is to inform applicants of a correction to the open date for PAR-21-265 "NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)."

The purpose of this notice is to inform applicants of a correction to the open date for PAR-21-266 "NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)".

The purpose of this notice is to inform applicants of a correction to the open date for PAR-21-267 "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)".

This notice informs the research community that the NINDS and NIA intend to publish a joint Funding Opportunity Announcement on the Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Alzheimers Disease Related Dementias. This Notice is being provided to allow potential applicants sufficient time to develop meaningful multidisciplinary collaborations and responsive projects. The FOA is expected to be published in January 2022 with an expected application due date in March 2022. This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.